MA47259A - Diagnostic - Google Patents

Diagnostic

Info

Publication number
MA47259A
MA47259A MA047259A MA47259A MA47259A MA 47259 A MA47259 A MA 47259A MA 047259 A MA047259 A MA 047259A MA 47259 A MA47259 A MA 47259A MA 47259 A MA47259 A MA 47259A
Authority
MA
Morocco
Prior art keywords
diagnostic
Prior art date
Application number
MA047259A
Other languages
English (en)
Inventor
John Hermon-Taylor
Original Assignee
Hav Vaccines Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hav Vaccines Ltd filed Critical Hav Vaccines Ltd
Publication of MA47259A publication Critical patent/MA47259A/fr

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • G01N33/5695Mycobacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267Gram-positive bacteria
    • C07K16/1289Mycobacteriaceae (F)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848Methods of protein analysis involving mass spectrometry
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/35Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycobacteriaceae (F)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/14Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Computational Biology (AREA)
MA047259A 2017-01-11 2018-01-11 Diagnostic MA47259A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1700487.0A GB201700487D0 (en) 2017-01-11 2017-01-11 Diagnostic

Publications (1)

Publication Number Publication Date
MA47259A true MA47259A (fr) 2019-11-20

Family

ID=58463962

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047259A MA47259A (fr) 2017-01-11 2018-01-11 Diagnostic

Country Status (14)

Country Link
US (3) US20200041509A1 (fr)
EP (1) EP3568698A1 (fr)
JP (1) JP7418215B2 (fr)
KR (1) KR102487240B1 (fr)
CN (1) CN110476065B (fr)
AU (1) AU2018208079B2 (fr)
BR (1) BR112019014299A2 (fr)
CA (1) CA3049498A1 (fr)
GB (1) GB201700487D0 (fr)
IL (1) IL267982A (fr)
MA (1) MA47259A (fr)
MX (1) MX2019007703A (fr)
SG (1) SG11201906189WA (fr)
WO (1) WO2018130836A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
GB201811382D0 (en) 2018-07-11 2018-08-29 Taylor John Hermon Vaccine
JP7166456B2 (ja) * 2018-08-01 2022-11-07 シーディーエックス・メディカル・アイピー・インコーポレイテッド 生体試料への拡張強化された合焦深度
WO2026041756A1 (fr) 2024-08-21 2026-02-26 Hav Vaccines Limited Traitement de la maladie de crohn au moyen d'un agent contre mycobacterium avium ssp. paratuberculosis

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8709803D0 (en) 1987-04-24 1987-05-28 Mcfadden J J Treatment of crohn's disease &c
US5225324A (en) 1987-04-24 1993-07-06 Bioscience International, Inc. Diagnostics for mycobacteria in public health, medical, and veterinary practice
GB9526178D0 (en) 1995-12-21 1996-02-21 Taylor John Hermon Novel polynuceotides and polypeptides in pathogenic mycobacteria and their use as diagnostics,vaccines and targets for chemotherapy
GB9806093D0 (en) 1998-03-20 1998-05-20 Taylor John Hermon Diagnostics and vaccines for mycobacterial infections of animals and humans
US20050232937A1 (en) * 2002-01-11 2005-10-20 Willemsen Petrus Theodorus J Paramycobacterial diagnostics and vaccines
US7074559B2 (en) * 2002-03-06 2006-07-11 Refents of the University of Minnesota Mycobacterial diagnostics
US20050112139A1 (en) * 2003-10-23 2005-05-26 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on factor H binding sites
CN101044160A (zh) * 2004-08-19 2007-09-26 蛋白质组系统知识产权有限公司 结核分支杆菌感染的诊断和治疗方法及所用试剂
ES2357968T3 (es) * 2005-02-16 2011-05-04 Cornell Research Foundation, Inc. Composiciones para desencadenar una respuesta inmunitaria contra mycobacterium avium subespecie paratuberculosis.
AU2006277828B2 (en) * 2005-08-09 2012-02-02 Hav Vaccines Limited Immunogenic constructs
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
JP2013500326A (ja) 2009-07-30 2013-01-07 ファイザー バクシーンズ エルエルシー 抗原性タウペプチドおよびその使用
CA2839865A1 (fr) * 2011-05-19 2012-11-22 University Of Central Florida Research Foundation, Inc. Detection de microbes par l'intermediaire de nanocapteurs d'hybridation a relaxation magnetique
WO2014016737A1 (fr) 2012-07-24 2014-01-30 Pfizer Inc. Nouveaux anticorps monoclonaux de poulet dirigés contre la protéine tau phosphorylée humaine et leurs utilisations
US20140116353A1 (en) * 2012-10-31 2014-05-01 Gilles R.G. Monif Fuidi herd management and risk stratification methods
US9879057B2 (en) * 2013-09-24 2018-01-30 University Of Guelph Biomarkers for Mycobacterium avium paratuberculosis (MAP)
GB201700487D0 (en) 2017-01-11 2017-02-22 Hermon-Taylor John Diagnostic
GB201811382D0 (en) * 2018-07-11 2018-08-29 Taylor John Hermon Vaccine

Also Published As

Publication number Publication date
US20230400462A1 (en) 2023-12-14
MX2019007703A (es) 2019-12-16
KR102487240B1 (ko) 2023-01-10
CN110476065A (zh) 2019-11-19
IL267982A (en) 2019-09-26
SG11201906189WA (en) 2019-08-27
US20220065855A1 (en) 2022-03-03
JP7418215B2 (ja) 2024-01-19
CN110476065B (zh) 2024-05-31
KR20190104589A (ko) 2019-09-10
US20200041509A1 (en) 2020-02-06
WO2018130836A1 (fr) 2018-07-19
CA3049498A1 (fr) 2018-07-19
JP2020507084A (ja) 2020-03-05
US12203934B2 (en) 2025-01-21
EP3568698A1 (fr) 2019-11-20
US11714085B2 (en) 2023-08-01
BR112019014299A2 (pt) 2020-02-18
GB201700487D0 (en) 2017-02-22
AU2018208079B2 (en) 2024-07-18
AU2018208079A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
EP3590403A4 (fr) Endoscope
CL2018000524S1 (es) Golilla
DE202018003363U8 (de) Handgelenkssphygmomanometer
EP3689221A4 (fr) Endoscope
DK3351526T3 (da) Diisopentylterephthalat
EP3689222A4 (fr) Endoscope
DK3571580T3 (da) Load-logical-and-shift-guarded-instruktion
DK3612237T3 (da) Genterapi
EP3615471A4 (fr) Immunocapteur plasmo-photoélectronique
DK3576686T3 (da) Brokbind
MA47259A (fr) Diagnostic
EP3656276A4 (fr) Endoscope
EP3607993A4 (fr) Raccord
EP3469357A4 (fr) Procédé de diagnostic
EP3656278A4 (fr) Endoscope
EP3656277A4 (fr) Endoscope
PL3510051T5 (pl) Karboksyalkilochitozan
EP3656281A4 (fr) Endoscope
DK3395159T3 (da) Ballepresse
DE112018006474A5 (de) Endoskop
EP3719250A4 (fr) Raccord
EP3656280A4 (fr) Endoscope
EP3656279A4 (fr) Endoscope
EP3626156A4 (fr) Endoscope
DK3391733T3 (da) Ballepresse